Accessibility Menu
Corbus Pharmaceuticals Stock Quote

Corbus Pharmaceuticals (NASDAQ: CRBP)

$17.38
(-2.0%)
-0.36
Price as of October 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$17.38
Daily Change
(-2.0%) $0.36
Day's Range
$17 - $18
Previous Close
$17.38
Open
$17.48
Beta
1.29
Volume
188,513
Average Volume
201,100
Market Cap
217.4M
Market Cap / Employee
$17.74M
52wk Range
$4.64 - $20.77
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$4.76
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Corbus Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CRBP+1.6%-41.45%-10.15%-80%
S&P+14.5%+93.32%+14.09%+242%

Corbus Pharmaceuticals Company Info

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.10M50.0%
Market Cap$84.43M-82.5%
Market Cap / Employee$3.02M0.0%
Employees2847.4%
Net Income-$17.66M-76.7%
EBITDA-$19.05M-76.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$20.33M-15.2%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.76M-69.0%
Short Term Debt$1.70M-86.3%

Ratios

Q2 2025YOY Change
Return On Assets-41.83%-6.1%
Return On Invested Capital180.28%94.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$16.60M-85.6%
Operating Free Cash Flow-$16.60M-85.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.890.950.450.66-86.46%
Price to Tangible Book Value1.890.950.450.66-86.46%
Enterprise Value to EBITDA-6.000.193.331.57-104.61%
Return on Equity-51.3%-59.3%-44.9%-49.0%-5.37%
Total Debt$3.61M$3.24M$2.86M$2.46M-83.40%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.